Malika Seth
Ashburn, VANPI 1679732093
Payments from drug & device makers
Across 151 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$381
- Supernus Pharmaceuticals, Inc.$371
- Otsuka America Pharmaceutical, Inc.$370
- Lundbeck LLC$250
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$250
- Ironshore Pharmaceuticals Inc.$188
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,861100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $381 |
| Supernus Pharmaceuticals, Inc. | 14 | $371 |
| Otsuka America Pharmaceutical, Inc. | 22 | $370 |
| Lundbeck LLC | 12 | $250 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $250 |
| Ironshore Pharmaceuticals Inc. | 10 | $188 |
| Corium, LLC | 9 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $163 |
| Johnson & Johnson | 7 | $129 |
| Alkermes, Inc. | 7 | $128 |
| Axsome Therapeutics, Inc. | 5 | $90 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Tris Pharma Inc | 4 | $70 |
| Eisai Inc. | 3 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Neos Therapeutics, LP | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$128
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 24 | $58,351 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 32 | $2,495 |
| Aripiprazole | 15 | $430 |
| Eszopiclone | 12 | $268 |
| Duloxetine Hcl | 16 | $227 |
| Buspirone Hcl | 16 | $171 |
| Alprazolam | 47 | $131 |
| Clonazepam | 20 | $123 |
| Lamotrigine | 13 | $123 |
| Trazodone Hcl | 15 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $370 | $58,35124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.